Clinical Trials Logo
  1. Home
  2. Chronic Idiopathic Constipation
  3. NCT01993875

Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation Clinical Trial

Official title:
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

Clinical Trial Summary

To evaluate the pharmacodynamics and tolerability of a liquid formulation of lubiprostone, as compared to matching placebo, when administered orally to subjects with chronic idiopathic constipation. Additionally, liquid formulation pharmacokinetics, including a comparison of fed and fasted pharmacokinetics, of the liquid formulation will be performed in a subset of subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01993875
Study type Interventional
Source Mallinckrodt
Contact
Status Completed
Phase Phase 3
Start date October 2013
Completion date January 2014
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02361749 - Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation Phase 4
Terminated NCT02239510 - Efficacy of Linaclotide to Senna for CIC N/A
Completed NCT01895543 - Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation Phase 3
Completed NCT01460225 - Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation Phase 4
Completed NCT02291679 - Trial of Linaclotide in Patients With Chronic Idiopathic Constipation Phase 3
Completed NCT01989234 - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation Phase 2
Completed NCT01674530 - Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation Phase 3
Completed NCT01429987 - The Plecanatide Chronic Idiopathic Constipation (CIC) Study Phase 2/Phase 3
Completed NCT01982240 - 12-Week Study of Plecanatide for CIC (The CIC3 Study) Phase 3
Completed NCT02590432 - An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Phase 4
Completed NCT02481947 - A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults Phase 3
Completed NCT01372423 - Evaluation of Clinical Equivalence Between Two Lubiprostone Products Phase 3
Completed NCT03054506 - The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT04804267 - Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation Phase 3
Completed NCT03879239 - Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation N/A
Completed NCT01053962 - SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation Phase 2
Completed NCT03097861 - Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo Phase 3
Completed NCT03551873 - A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
Completed NCT02819310 - An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults Phase 3
Completed NCT02819297 - BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults Phase 3